Trial Profile

A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2024 Results presented in the Teva Pharmaceuticals Media Release.
01 Jun 2024 According to Teva Pharmaceuticals media release, results from this trial were presented at the Psych Congress Elevate 2024 Annual Meeting taking place from May 30 -June 2 in Las Vegas, Nevada.
06 Sep 2023 According to Teva Pharmaceuticals media release, long-term safety, tolerability, and effectiveness of TV-46000, a long-acting subcutaneous antipsychotic (LASCA), in patients with schizophrenia will be presented at Psych Congress on September 6-10 in Nashville, TN.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com